HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Abdominal Pain (Pain, Abdominal)

Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue injuries, or diseases.
Also Known As:
Pain, Abdominal; Abdominal Pains; Pains, Abdominal
Networked: 6722 relevant articles (391 outcomes, 392 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Diarrhea
2. Nausea
3. Constipation
4. Fever (Fevers)
5. Vomiting

Experts

1. Fichna, Jakub: 11 articles (11/2015 - 01/2012)
2. Talley, Nicholas J: 11 articles (05/2009 - 05/2002)
3. Chey, William D: 8 articles (11/2012 - 02/2005)
4. Talley, N J: 8 articles (03/2010 - 09/2000)
5. SaƂaga, Maciej: 6 articles (10/2015 - 03/2014)
6. Benninga, Marc A: 6 articles (04/2015 - 07/2006)
7. McCallum, Richard W: 6 articles (01/2014 - 10/2005)
8. Tack, J: 6 articles (01/2014 - 06/2006)
9. Camilleri, M: 6 articles (06/2013 - 01/2000)
10. Conwell, Darwin L: 6 articles (03/2013 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Abdominal Pain:
1. linaclotideIBA
2. Anti-Bacterial Agents (Antibiotics)IBA
3. Prednisolone (Predate)FDA LinkGeneric
4. AmylasesFDA Link
5. tegaserod (Zelnorm)FDA Link
01/01/2004 - "Tegaserod did not significantly improve the patients' individual symptoms of abdominal pain and discomfort although bowel habit showed a statistically significant improvement with tegaserod 4 mg and there was a non-significant trend in favour of tegaserod 12 mg. When GI symptoms were assessed separately, those indicative of GI motility such as number of bowel movements and days without bowel movements were generally improved with tegaserod although the proportion of patients experiencing diarrhoea was significantly higher in the tegaserod 12 mg group compared with placebo (RR 2.75, 95% CI 1.90, 3.97), with a number needed to harm (NNH) of 20. "
11/01/2004 - "Patients who were treated with tegaserod had an overall improvement in IBS symptoms (Subject's Assessment of Global Relief) as well as in secondary end points, such as abdominal pain and discomfort, stool consistency, change in bowel movements and relief of bloating. "
01/01/2004 - "Tegaserod has been assessed in a number of international multicentre trials and its use leads to an improvement in abdominal pain and bowel dysfunction as well as global well-being, at the expense of remarkably few adverse effects. "
04/01/2003 - "In clinical trials with tegaserod, the Subject's Global Assessment (SGA) of Relief (a global measure that includes overall wellbeing, abdominal pain/discomfort, and bowel function) was used to identify responders. "
01/01/2008 - "In the group with other indications to start tegaserod therapy, moderate or significant relief of abdominal pain and bloating was noted in 64% and 68% of patients, respectively. "
6. Opioid Analgesics (Opioids)IBA
7. Morphine (MS Contin)FDA LinkGeneric
8. Misoprostol (Cytotec)FDA LinkGeneric
9. LactoseFDA LinkGeneric
10. rifaximin (L 105)FDA Link

Therapies and Procedures

1. Aftercare (After-Treatment)
2. Cholecystectomy
3. Drug Therapy (Chemotherapy)
4. Enema (Enemas)
5. Appendectomy